Direct demonstration in dogs of the absence of lethal reperfusion injury

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 1, 1997, Pages 105-107

  Ganz, William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DOG; HEART INFARCTION; HEART MUSCLE REPERFUSION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0031020554     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017535509682     Document Type: Article

References (13)

1. Reimer KA, Murry CE, Richard VJ. The role of neutrophils and free radicals in the ischemic-reperfused heart; why the confusion and controversy? J Mol Cell Cardiol 1989;21: 1225-1239.
2. Hoffman M, Genth K, Schaper W. The influence of reperfusion on infarct size after experimental coronary artery occlusion. Basic Res Cardiol 1980;75:572-582.
3. Ganz W, Watanabe I, Kanamasa K, Yano J, Han DS, Fishbein MC. Does reperfusion extend necrosis? A study in a single territory of myocardial ischemia, half reperfused and half not reperfused. Circulation 1989;82:1020-1033.
4. Zahger D, Yano J, Chaux A, Fishbein MC, Ganz W. Absence of lethal reperfusion injury after 3 hours of reperfusion. Circulation 1995;91:2989-2994.
5. Narula J, Nicol PD, Southern JF, et al. Evaluation of myocardial infarct size before and after reperfusion: Dual tracer imaging with radiolabeled antimyosin antibody. J Nuclear Med 1994;35:1076-1085.
6. Farb A, Kolodgie FD, Jenkins M, Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: Pathologic evidence. J Am Coll Cardiol 1993;21: 1245-1253.
7. Khaw BA, Strauss HW, Moore R, Fallon JT, Yasuda T, Gold HK, Haber E. Myocardial damage delineated by 111-In antimyosin Fab and technetium-99m pyrophosphate. J Nuclear Med 1987;28:76-82.
8. Takeda K, LaFrance ND, Weisman HF, Wagner HN, Becker LC. Comparison of indium-111 antimyosin antibody and technetium-99m pyrophosphate localization in reperfused and nonreperfused myocardial infarction. J Am Coll Cardiol 1991;17:519-526.
9. Kent SP. Intracellular plasma protein: A manifestation of cell injury in myocardial ischemia. Nature 1966;210: 1279-1281.
10. Jennings RB, Reimer KA, Steenbergen C. Myocardial ischemia revisited: The osmolar load, membrane damage and reperfusion. J Mol Cell Cardiol 1986;18:769-780.
11. Frame LH, Lopez JA, Khaw BA, Fallon JT, Haber E, Powell WJ Jr. Early membrane damage during coronary reperfusion in dogs: Detection by radiolabeled anticardiac myosin (Fab')2. J Clin Invest 1983;72:535-544.
12. Flaherty T, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994;89: 1982-1991.
13. Wall TC, Califf RM, Blankenship J, et al. and the TAMI 9 Research Group. Intravenous fluosol in the treatment of acute myocardial infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 trial. Circulation 1994;90:114-120.